Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Scinai Immunotherapeutics Ltd. SCNI

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update

Posted on August 15, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today published its financial results for the second quarter ended June … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity

Posted on August 13, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the signing of a definitive Loan Restructuring Agreement with the European Investment … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study

Posted on July 15, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q1 2024 Financial Reports, Business Update

Posted on July 2, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting on its financial results for the … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Posted on June 7, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company announced today that on June 5, 2024, it received a formal … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases FY 2023 Financial Results, Provides Business Update

Posted on May 16, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting its full-year financial results for 2023 … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Nasdaq Delisting Notification and Appeal, ADS Ratio Change

Posted on May 6, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today announced that it has received a staff determination letter on … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma

Posted on April 8, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, through its contract development and manufacturing organization (“CDMO”) business unit, Scinai Bioservices, has signed a five-year Master Service Agreement (“MSA”) with Ayana Pharma Ltd. As … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024

Posted on March 12, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month’s BIO-Europe Spring 2024 conference. The conference is … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales

Posted on February 13, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head of business development and sales. … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment